Cartesian Therapeutics (STU:1S70) Total Assets : €299.19 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cartesian Therapeutics Total Assets?

Cartesian Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was €299.19 Mil.

Warning Sign:

If a company builds assets at 82.5% a year, faster than its revenue growth rate of 47.4% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Cartesian Therapeutics's average Total Assets Growth Rate was 645.10% per year. During the past 3 years, the average Total Assets Growth Rate was 104.30% per year. During the past 5 years, the average Total Assets Growth Rate was 82.50% per year.

During the past 10 years, Cartesian Therapeutics's highest 3-Year average Total Assets Growth Rate was 104.30%. The lowest was -7.50%. And the median was 47.90%.

Total Assets is connected with ROA %. Cartesian Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was -72.24%. Total Assets is also linked to Revenue through Asset Turnover. Cartesian Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.02.

Cartesian Therapeutics Total Assets Historical Data

The historical data trend for Cartesian Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Total Assets Chart

Cartesian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

89.61

135.99

141.50

156.60

279.73

Cartesian Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															145.42	128.76	99.35	279.73	299.19

Cartesian Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cartesian Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-403.649	+	683.38
	=	279.73

Cartesian Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-107.456	+	406.646
	=	299.19

Cartesian Therapeutics (STU:1S70) Total Assets Explanation

Total Assets is connected with ROA %.

Cartesian Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-209.112	/	( (279.731	+	299.19)	/ 2 )
	=	-209.112	/	289.4605
	=	-72.24 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cartesian Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	5.373	/	( (279.731	+	299.19)	/ 2 )
=	5.373	/	289.4605
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cartesian Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (STU:1S70) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (STU:1S70) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

RNAC:USA 1S7:Germany

Address

65 Grove Street, Watertown, MA, USA, 02472

Website

https://www.selectabio.com

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Cartesian Therapeutics (STU:1S70) Headlines

No Headlines